Foundation Medicine Announces Executive Leadership Transition
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Foundation Medicine, Inc. today announced the appointment of Cindy Perettie as chief executive officer, effective February 4, 2019. Ms. Perettie will succeed Troy Cox. Ms. Perettie brings more than two decades of scientific and commercial experience with global biopharmaceutical organizations, most recently having served as a senior vice president in global oncology product strategy for Roche’s Oncology unit.
“Cindy brings proven global, strategic, and operational biopharma leadership and oncology expertise to lead Foundation Medicine through the next phase of its growth,” said Troy Cox, chief executive officer at Foundation Medicine. “As we look ahead, the advancements across our molecular information portfolio position the Company to continue to lead in precision oncology and Cindy is well poised to accelerate our work to bring these advances forward and transform cancer care for patients. I look forward to collaborating with her and the senior management team in transitioning the chief executive officer role, as we together work toward supporting the Company’s mission. My time at Foundation Medicine has been one of the most rewarding of my career. The mission, the people, and the impressive progress we have made together has been life-changing for me. I am grateful to carry that with me into my next chapter.”
Ms. Perettie joins Foundation Medicine from Roche, where she's led one of the largest global oncology portfolios. She has led several successful product launches in the U.S. and abroad for Roche and Genentech across the oncology portfolio, including in breast cancer and hematology. Ms. Perettie began her tenure at Genentech as a program team leader for bevacizumab, focused on lung cancer, breast cancer, gastrouterine cancer and melanoma. She has held roles of increasing responsibility at Genentech since joining in 2004, including vice president of global regulatory operations and regional head of Europe, Middle East and Africa operations and global development.
Ms. Perettie took a hiatus from Genentech in 2012 to join Sarah Cannon Research Institute (SCRI) as President, Global Development Innovations. There, she was responsible for leading and growing SCRI’s contract research organization business globally, driving the execution of critical oncology clinical trials during her tenure.
Before joining Genentech, Ms. Perettie lead portfolio management at IVAX Pharmaceuticals and was the director of global program management at Élan Corporation. She started her career as a senior research associate at Johns Hopkins University, before taking on a research scientist associate director role at Chiron Corporation.
Ms. Perettie holds a master’s degree of marketing and finance from St. Mary’s College of California and received her bachelor’s degree in biology, with a minor in chemistry from State University of New York College at Potsdam. She also studied at Johns Hopkins University.
About Foundation Medicine
Foundation Medicine is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient's unique cancer. The company offers a full suite of comprehensive genomic profiling assays to identify the molecular alterations in a patient’s cancer and match them with relevant targeted therapies, immunotherapies and clinical trials. Foundation Medicine’s molecular information platform aims to improve day-to-day care for patients by serving the needs of clinicians, academic researchers and drug developers to help advance the science of molecular medicine in cancer. For more information, please visit www.FoundationMedicine.com or follow Foundation Medicine on Twitter (@FoundationATCG).
Foundation Medicine® is a registered trademark of Foundation Medicine, Inc.
Lee-Ann Murphy, 617-245-3077
Source: Foundation Medicine, Inc.